Company / Return on Equity (ROE)
Inhibikase Therapeutics, Inc. Return on Equity (ROE) History
FY2021-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-173.3%
FY2024
5-year range
-173.3% / -29.1%
FY2021-FY2024
Trend
-102.0%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Inhibikase Therapeutics, Inc. reports negative total equity of -173.3% in FY2024. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-173.3% in FY2024 with a 3-year CAGR of -144.2%.
Declined from -38.5% to -173.3% over the past 2 years.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -144.2pp
- 5-Year Change
- -
- 10-Year Change
- -
Key checks
Key Insights
- Inhibikase Therapeutics, Inc.'s return on equity (roe) has declined for 3 consecutive years.
- In FY2024, return on equity (roe) decreased 102.0% year-over-year.
Company context
Key Data Points
- Altman Z-Score 0.11 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2024 | -173.3% | -102.0% |
| FY2023 | -85.8% | -123.0% |
| FY2022 | -38.5% | -32.2% |
| FY2021 | -29.1% | - |
As of FY2024 · SEC 10-K · Updated Jun 24, 2026